Metastatic breast cancer trials recruiting in Illinois

All Metastatic breast cancer trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Zion
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
  NCT06099769 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Skokie
• CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
  NCT05029999 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Illinois: Chicago
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
  NCT06062498 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
  NCT03824145 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · Illinois: Maywood
• Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
  NCT05455619 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Hinsdale
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago, New Lenox, Orland Park
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Peoria, Urbana
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
  NCT06072612 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago, Springfield, Urbana